Cell Source, Inc. CLCS OTC

Other OTC • Healthcare • Biotechnology • US • USD

SharesGrow Score

18/100

0/4 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

Income Statement Balance Sheet Cash Flow Statement

Annual Quarterly

Cell Source, Inc. (CLCS) reported total assets of $286.5K and total liabilities of $19.08M for fiscal year 2024, resulting in total equity of $-18.8M.

The company held $74.63K in cash and short-term investments. Total debt stood at $10.07M, with net debt of $9.99M. The Debt-to-Equity (D/E) ratio was -0.54 (conservative).

Current ratio is 0.02, which may signal tight short-term liquidity. Interest coverage is -3.3x (weak).

Criteria supported by this page:

HEALTH (0/100, Fail) — the balance sheet shows elevated risk in debt or liquidity metrics
MOAT (28/100) — Total assets $286.5K and equity $-18.8M support the company's competitive scale

Overall SharesGrow Score: 17/100 with 0/7 criteria passed.

SharesGrow 7-Criteria Score

18/100

SG Score

View full scorecard →

—

VALUE

N/A

No coverage

—

FUTURE

N/A

No coverage

✗

PAST

0/100

→ Income

✗

HEALTH

0/100

Debt-to-Equity & liquidity

Proven by this page

✗

MOAT

28/100

→ Income

GROWTH

45/100

→ Income

—

INCOME

N/A

No coverage

Cell Source, Inc. Balance Sheet History

Metric	FY2024	FY2023	FY2022	FY2021
Total Assets	$286.5K	$195.17K	$409.85K	$313.77K
Total Liabilities	$19.08M	$15.81M	$13.04M	$10.14M
Total Debt	$10.07M	$9.25M	$7.9M	$6.47M
Cash & Investments	$74.63K	$22.2K	$222.67K	$93.1K
Total Stockholders Equity	$-18.8M	$-15.61M	$-12.63M	$-9.83M